Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).

Employees

1,271

Sector

Biotechnology & Medical Research

Calendar

02-18 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
05/12/25	204.00 $	-0.51%	2,160,144
04/12/25	205.04 $	-0.84%	1,861,198
03/12/25	206.78 $	+0.09%	2,544,385
02/12/25	206.60 $	-2.28%	1,383,927
01/12/25	211.41 $	+1.75%	1,868,208

Delayed Quote Nasdaq, December 05, 2025 at 09:00 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

204.00USD

Average target price

222.78USD

Spread / Average Target

+9.20%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 21:00:00 05/12/2025 GMT			5-day change	1st Jan Change
204.00 ^USD	-0.51%		-1.81%	+195.48%

12-05	Insmed Insider Sold Shares Worth $2,199,915, According to a Recent SEC Filing	MT
12-04	Insmed reports inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE

Capitalization	43.51B 37.4B 35.04B 32.66B 60.32B 3,916B 65.61B 410B 158B 1,849B 163B 160B 6,762B	P/E ratio 2025 *	-33.1x	P/E ratio 2026 *	-59.3x
Enterprise value	43.06B 37.01B 34.68B 32.32B 59.7B 3,875B 64.93B 406B 157B 1,830B 162B 158B 6,692B	EV / Sales 2025 *	84x	EV / Sales 2026 *	35x
Free-Float	98.99%	Yield 2025 *	-	Yield 2026 *	-

12-05	Insmed Insider Sold Shares Worth $2,199,915, According to a Recent SEC Filing	MT
12-04	Insmed reports inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
12-04	Rothschild & Co Redburn Initiates Coverage on Insmed With Buy Rating, $263 Price Target	MT
12-03	Insmed Insider Sold Shares Worth $1,841,101, According to a Recent SEC Filing	MT
12-02	Insmed Incorporated Presents at Evercore 8th Annual Healthcare Conference, Dec-02-2025 11:15 AM
12-01	Mizuho Raises Price Target on Insmed to $256 From $196, Keeps Outperform Rating	MT
11-18	Insmed Says European Commission Approves Brinsupri for Treatment of Non-Cystic Fibrosis Bronchiectasis	MT
11-18	Insmed Incorporated Receives European Commission Approval For BRINSUPRI As First Treatment For Non-Cystic Fibrosis Bronchiectasis	CI
11-18	Insmed Incorporated Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 08:30 AM
11-05	Insmed Insider Sold Shares Worth $4,985,911, According to a Recent SEC Filing	MT
10-31	Insmed Shares Likely to Gain From Brinsupri Sales, Untapped Pipeline, UBS Says	MT
10-31	RBC Raises Price Target on Insmed to $215 From $139, Keeps Outperform Rating	MT
10-31	Big Tech's Haunted Bill

12-04	Rothschild & Co Redburn Initiates Coverage on Insmed With Buy Rating, $263 Price Target	MT
12-01	Mizuho Raises Price Target on Insmed to $256 From $196, Keeps Outperform Rating	MT
10-31	Insmed Shares Likely to Gain From Brinsupri Sales, Untapped Pipeline, UBS Says	MT
10-31	RBC Raises Price Target on Insmed to $215 From $139, Keeps Outperform Rating	MT
10-31	UBS Adjusts Insmed Price Target to $223 From $194, Maintains Buy Rating	MT

Insmed Incorporated Share Price

Equities

INSM

US4576693075

Biotechnology & Medical Research

Valuation: Insmed Incorporated

Chart: Insmed Incorporated

Latest news: Insmed Incorporated

Last Transcript: Insmed Incorporated

Analysts' recommendations: Insmed Incorporated

Press Releases: Insmed Incorporated

News in other languages: Insmed Incorporated

Quotes and Performance

Course Extremes

Managers and Directors: Insmed Incorporated

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

12-04	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	PR
11-20	Insmed wins first EU approval for non-cystic fibrosis bronchiectasis treatment	AQ
11-19	Insmed Incorporated - European Commission Approves BRINSUPRI as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union	AQ
11-18	European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union	PR
11-13	Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good	PR

10-31	Wall Street : La facture qui hante la Big Tech
10-03	Wall Street : Au sommet, encore
10-02	L'idylle de Wall Street avec la faiblesse
09-03	Wall Street : Antitrust en recul, rendements en hausse
08-20	Wall Street : Le consommateur américain fatigue

1 day	-0.51%
1 week	-1.81%
Current month	-1.81%
1 month	+9.16%
3 months	+40.59%
6 months	+180.45%
Current year	+195.48%

1 week	202.68	212.75
1 month	182.53	212.75
Current year	60.4	212.75
1 year	60.4	212.75
3 years	16.04	212.75
5 years	16.04	212.75
10 years	9.02	212.75

Manager	Title	Age	Since
Will Lewis CEO	Chief Executive Officer	56	09/09/2012
Sara Bonstein DFI	Director of Finance/CFO	44	30/01/2020
Martina Flammer CTO	Chief Tech/Sci/R&D Officer	61	18/12/2019

Director	Title	Age	Since
Melvin Sharoky CHM	Chairman	74	15/06/2009
Will Lewis CHM	Chairman	56	07/11/2018
David McGirr BRD	Director/Board Member	70	29/10/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
INSMED INCORPORATED	-0.51%	-1.81%	+170.81%	+925.64%	43.51B
ARGENX SE	-2.68%	-1.46%	+30.24%	+105.16%	54.89B
WUXI APPTEC CO., LTD.	+0.90%	-0.87%	+75.84%	+15.31%	38.12B
BIONTECH SE	+0.26%	-6.69%	-19.01%	-42.27%	23.14B
GENMAB A/S	-1.45%	-0.34%	+30.97%	-37.78%	19.5B
WUXI BIOLOGICS (CAYMAN) INC.	-0.97%	+4.69%	+98.42%	-40.74%	17.25B
AKESO, INC.	+0.57%	+0.98%	+89.61%	+302.27%	14.68B
SUMMIT THERAPEUTICS INC.	-2.66%	+2.35%	+4.51%	+2,232.48%	14.12B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+2.45%	+0.79%	+147.98%	-	13.78B
MADRIGAL PHARMACEUTICALS, INC.	-1.52%	-3.30%	+84.41%	+692.23%	13.11B
Average	-0.56%	-0.68%	+71.38%	+461.37%	25.21B
Weighted average by Cap.	-0.75%	-1.20%	+72.86%	+374.47%

	2025 *	2026 *
Net sales	513M 441M 413M 385M 711M 46.14B 773M 4.83B 1.86B 21.79B 1.92B 1.88B 79.68B	1.22B 1.05B 986M 919M 1.7B 110B 1.85B 11.53B 4.45B 52.02B 4.59B 4.5B 190B
Net income	-1.22B -1.05B -982M -915M -1.69B -110B -1.84B -11.48B -4.43B -51.81B -4.58B -4.48B -189B	-730M -628M -588M -548M -1.01B -65.73B -1.1B -6.88B -2.66B -31.04B -2.74B -2.68B -114B
Net Debt	-447M -384M -360M -336M -620M -40.24B -674M -4.21B -1.63B -19.01B -1.68B -1.64B -69.5B	-650M -559M -524M -488M -901M -58.51B -980M -6.12B -2.36B -27.64B -2.44B -2.39B -101B